Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRT Effect on MASLD Pilot Study
NCT06704516Phase 1Recruiting
- Sponsor
- University of Oxford
- Start
- Jan 2025
- Primary completion
- Aug 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of semaglutide + estradiol + progesterone in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by University of Oxford. Primary endpoint: Recruitment into an experimental medicine study investigating the impact of HRT on MASLD at 7 months. Started Jan 2025; status: recruiting.
02
Drugs
semaglutide + estradiol + progesterone
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT06704516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06704516.